CLINICAL TRIALS PROFILE FOR ALDESLEUKIN

All Clinical Trials for aldesleukin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000680 ↗	A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC	Completed	Applied Immunesciences	Phase 1	1969-12-31	1) To determine whether it is possible to remove and culture (increase in number and activate) in the laboratory, CD8(+) lymphocytes (white blood cells) from HIV-infected patients receiving zidovudine (AZT); 2) To determine the toxicity of returning to the patients intravenously the expanded and activated autologous cells (given to the patient from whom they were taken), with and without giving the patients recombinant interleukin-2 ( aldesleukin; IL-2 ) at the same time; 3) To radiolabel (mark) the CD8(+) lymphocytes with Indium 111, and then scan the patients to determine the distribution of the CD8(+) lymphocytes in those who are and are not given IL-2 infusions; 4) To determine the toxicity of IL-2 given at the same time with autologous CD8(+) lymphocytes; 5) To measure changes in the immunology of the subjects following these treatments. CD8(+) cells are suppressor/killer lymphocyte cells that act to limit replication of viruses. It is hoped that the reinfusion of activated autologous CD8(+) cells into patients with AIDS will help to control opportunistic infections such as cytomegalovirus and toxoplasmosis (two of the leading causes of sickness and death in AIDS patients). This treatment may also stop the HIV virus from replicating (reproducing itself) in the AIDS patient. Further activation of these cells, once infused, may be necessary. It is hoped that IL-2 will stimulate the patient's immune system against the AIDS virus along with the activated CD8(+) cells. Thus, IL-2 will be given, and its effects studied.
NCT00000680 ↗	A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	1) To determine whether it is possible to remove and culture (increase in number and activate) in the laboratory, CD8(+) lymphocytes (white blood cells) from HIV-infected patients receiving zidovudine (AZT); 2) To determine the toxicity of returning to the patients intravenously the expanded and activated autologous cells (given to the patient from whom they were taken), with and without giving the patients recombinant interleukin-2 ( aldesleukin; IL-2 ) at the same time; 3) To radiolabel (mark) the CD8(+) lymphocytes with Indium 111, and then scan the patients to determine the distribution of the CD8(+) lymphocytes in those who are and are not given IL-2 infusions; 4) To determine the toxicity of IL-2 given at the same time with autologous CD8(+) lymphocytes; 5) To measure changes in the immunology of the subjects following these treatments. CD8(+) cells are suppressor/killer lymphocyte cells that act to limit replication of viruses. It is hoped that the reinfusion of activated autologous CD8(+) cells into patients with AIDS will help to control opportunistic infections such as cytomegalovirus and toxoplasmosis (two of the leading causes of sickness and death in AIDS patients). This treatment may also stop the HIV virus from replicating (reproducing itself) in the AIDS patient. Further activation of these cells, once infused, may be necessary. It is hoped that IL-2 will stimulate the patient's immune system against the AIDS virus along with the activated CD8(+) cells. Thus, IL-2 will be given, and its effects studied.
NCT00000728 ↗	Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To evaluate the short-term effects of administering zidovudine ( AZT ) at the same time with increasing doses of aldesleukin ( interleukin-2; IL-2 ) in patients with persistent generalized lymphadenopathy syndrome ( PGL ). The effects to be studied include safety or toxicity, how quickly the drugs are used in the body, effects on the immune system, effects on HIV, concentrations in body fluids, and how quickly the drugs are cleared by the kidneys. The trial will establish the maximum tolerated dose ( MTD ) and will be a pilot study to determine the dose that has the greatest effect in the immune system. AZT has been shown to be effective in HIV-related disease. IL-2 has been shown to increase immune responses and correct immune problems caused by HIV in the test tube. IL-2 has also been effective in treating Kaposi's sarcoma in a number of patients. Because of the clinical activities of these two drugs and because their toxicities and mechanisms of action do not overlap, it may be beneficial to combine the two drugs with their antiviral and immune stimulatory effects.

Clinical Trial Conditions for aldesleukin

Condition Name

Condition Name for aldesleukin
Intervention	Trials
HIV Infections	32
Metastatic Melanoma	31
Melanoma	23

Condition MeSH

Condition MeSH for aldesleukin
Intervention	Trials
Melanoma	82
HIV Infections	33
Carcinoma, Renal Cell	32

Clinical Trial Locations for aldesleukin

Trials by Country

Trials by Country for aldesleukin
Location	Trials
United States	709
Canada	30
Australia	30
United Kingdom	23
France	10

Trials by US State

Trials by US State for aldesleukin
Location	Trials
Maryland	86
California	52
Texas	45
New York	40
Washington	30

Clinical Trial Progress for aldesleukin

Clinical Trial Phase

Clinical Trial Phase for aldesleukin
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	11
Phase 4	4

Clinical Trial Status

Clinical Trial Status for aldesleukin
Clinical Trial Phase	Trials
Completed	133
Terminated	47
RECRUITING	32

Clinical Trial Sponsors for aldesleukin

Sponsor Name

Sponsor Name for aldesleukin
Sponsor	Trials
National Cancer Institute (NCI)	150
National Institute of Allergy and Infectious Diseases (NIAID)	29
Fred Hutchinson Cancer Research Center	21

Sponsor Type

Sponsor Type for aldesleukin
Sponsor	Trials
Other	265
NIH	193
Industry	72

Aldesleukin (Recombinant IL-2) Clinical Trials Update, Market Analysis, and Projection

Last updated: April 29, 2026

What is aldesleukin’s current clinical and regulatory positioning?

Aldesleukin is a recombinant form of interleukin-2 (IL-2) used historically in oncology and approved in multiple jurisdictions for specific indications. In practice, the commercial footprint today is tied to legacy indications, periodic guideline cycles, and the competitive set of IL-2 alternatives (including pegylated IL-2 and other cytokine pathways), plus changes in first-line standards in metastatic disease.

Product and ownership snapshot

Aldesleukin is marketed under the brand Proleukin in the US and in other territories under varying local brand names. The brand has faced long-run erosion from new immuno-oncology standards and from competing IL-2 formulations and regimens.

What is the active “clinical trials update” state?

As of the present time, aldesleukin’s clinical program is not characterized by a single dominant late-stage development track that is clearly replacing its legacy label. Trial activity exists across observational and interventional lines, often focused on:

• older or post-label questions (sequence, combination feasibility in defined patient subgroups)
• operational endpoints (patterns of care, toxicity management)
• historical cohorts and registry follow-up
• combination explorations with checkpoint inhibitors or targeted agents (where feasible)

The clinical development pattern for aldesleukin is consistent with a mature asset in an immuno-oncology landscape where standards of care evolve faster than cytokine monotherapy programs.

Which clinical trial themes still matter for value realization?

Aldesleukin’s future commercial value is most sensitive to two drivers: (1) whether regulators expand label scope through meaningful efficacy in a defined competitive segment, and (2) whether clinicians maintain use in niches where IL-2 still has a durable role. Trial activity that tends to move practice is usually constrained by a narrow therapeutic window and toxicity burden, so the highest-probability value themes look like:

1. Lower-toxicity administration frameworks

• trial designs that standardize dosing schedules
• toxicity mitigation that enables broader outpatient or more tolerable use

2. Combination strategies in biomarker-defined subgroups

• cytokine plus immunotherapy sequences
• subgroup enrichment based on response or immune phenotype

3. Real-world evidence (RWE) that preserves payer and guideline confidence

• outcomes aligned to current practice settings
• safety documentation that reduces hesitation in community use

What is the market size, demand structure, and pricing pressure?

Demand drivers

Aldesleukin demand historically tracks:

• metastatic renal cell carcinoma (mRCC) treatment availability in cycles where IL-2 remained part of practice
• melanoma relapse settings where high-dose IL-2 had a defined niche
• centers of excellence’ willingness to manage cytokine toxicity

Key market constraints

• Practice shift: checkpoints and targeted therapies reduced high-dose IL-2 share in many settings.
• Toxicity: ICU-level monitoring and adverse event burden increased barriers outside tertiary centers.
• Competition: other IL-2 and IL-2-based platforms compete for clinician attention and payer willingness.
• Supply and stewardship: mature products often face tighter procurement scrutiny.

Pricing and payer dynamics

For mature biologics:

• price realization depends on formulary position, prior authorization behavior, and bundle structures for administration.
• procurement shifts toward lower-cost regimens when clinical benefit is not clearly incremental in the current first-line environment.

Market structure (how buyers think)

Buyers generally evaluate aldesleukin through:

• expected utilization by reference centers
• protocol adherence and monitoring capability
• bundled administration cost versus oncology infusion economics
• comparative clinical outcomes versus checkpoint-based pathways

How is competition reshaping IL-2 use?

Aldesleukin competes on multiple dimensions:

• Toxicity vs efficacy balance: clinicians prefer IL-2 options that reduce severe toxicity or improve tolerability.
• Treatment convenience: dosing frequency and inpatient versus outpatient feasibility matter.
• Position in the treatment line: IL-2’s historical role in second-line or salvage has narrowed as frontline standards expanded.

Pegylated IL-2 products and IL-2 variants, plus broader immune-therapy regimens, pull demand and influence guideline emphasis.

What is the near-term market outlook?

Base-case expectations (12 to 24 months)

• Sales volume: flat to modest decline is the typical path for legacy high-toxicity cytokines absent label expansion.
• Sales value: subject to price pressure from payer procurement and competitive substitution.
• Utilization geography: concentration in experienced centers persists.

Upside scenarios (growth triggers)

• Label expansion that targets a competitive niche with demonstrable benefit
• Combination evidence that produces clinically meaningful outcomes in settings where clinicians currently lack options
• Operational adoption: toxicities controlled enough to expand use beyond referral centers

Downside scenarios

• further erosion from first-line and second-line standard consolidation
• continued payer scrutiny tied to high administration cost and limited population size
• manufacturing, supply, or stewardship restrictions in some markets

What is the mid-term projection (3 to 5 years) and what drives it?

Aldesleukin’s mid-term trajectory is mostly a function of whether the product regains any meaningful label relevance in a modern standards-of-care pathway.

Projection framework

Because aldesleukin is mature, projections should be treated as scenario-based around utilization rather than assuming category growth.

Scenario table: utilization-driven outlook

Scenario	Core assumption	3-5 year impact on net sales (direction)	Main drivers
Base	No meaningful new label expansion; usage remains center-concentrated	Flat to down	Standard-of-care replacement, toxicity burden, procurement pressure
Bull	Clear evidence supports a defined combination or subgroup use with guideline adoption	Up	Treatment line re-entry, improved tolerability framework, payer uptake
Bear	Further displacement by competing IL-2/IO regimens and tightening stewardship	Down more	Limited patient eligibility, reduced center prescribing

What do investors and R&D strategists watch next?

For a mature IL-2 product, the market does not move on small signals. The key watch items are:

1. Any regulatory action tied to efficacy endpoints

• label expansions, supplemental indications, or major label updates that change clinical positioning

2. Trial readouts that translate into practice

• toxicity-adjusted schedules
• combination regimens with consistent response durability

3. Guideline references

• oncology society updates that incorporate or de-emphasize IL-2’s role in specific populations

4. Real-world adoption

• center uptake, protocol adherence, and payer approval patterns

What is the most actionable clinical and commercial thesis for aldesleukin?

Aldesleukin’s commercial future is not “category growth driven.” It is “competitive positioning driven.” The product’s value depends on whether trial activity generates:

• a defendable new label or a modern sequence claim
• a toxicity management narrative that removes practical barriers
• payer-credible outcomes in a defined segment

Absent that, utilization trends generally follow the broader immuno-oncology displacement pattern.

---

Key Takeaways

• Aldesleukin is a mature IL-2 biologic whose current clinical activity is dominated by center-led practice questions and combination or operational research rather than a single decisive late-stage replacement program.
• Demand has been structurally constrained by evolving immuno-oncology standards, toxicity burden, and payer procurement dynamics that prefer easier-to-administer regimens with broader line coverage.
• Market outlook is utilization-driven and scenario-based: base-case is flat to declining net sales; bull-case requires clear, label-relevant clinical differentiation with guideline uptake; bear-case follows further displacement and stewardship tightening.
• The highest-impact signals for commercial performance are regulatory label changes, readouts that translate into practice, and real-world adoption in centers capable of IL-2 monitoring.

---

FAQs

1. Is aldesleukin still used in standard oncology pathways today?
   Yes, but primarily in narrower, guideline-defined niches and in centers with high IL-2 experience; widespread first-line dominance has not returned.

2. What is the main reason IL-2 adoption is limited versus newer immunotherapies?
   Toxicity management and administration burden, plus reduced comparative utility versus checkpoint and targeted regimens in broader patient groups.

3. What trial outcomes would most likely expand aldesleukin’s market?
   Efficacy signals that support a specific modern combination or sequence with a tolerability framework that enables broader use.

4. How does payer behavior affect aldesleukin commercialization?
   Payers and procurement teams often restrict high-admin-cost therapies when incremental benefit is unclear in current treatment lines, pushing uptake to narrower indications.

5. What competitive set pressures aldesleukin?
   IL-2 derivatives and IL-2-based platforms, plus broader immuno-oncology regimens that capture most eligible patients in contemporary practice.

---

References

1. FDA. Proleukin (aldesleukin) Prescribing Information. U.S. Food and Drug Administration.
2. EMA. Proleukin (aldesleukin) product information and summary documents. European Medicines Agency.
3. National Cancer Institute. Aldesleukin (IL-2) information and trial-related overviews. U.S. National Institutes of Health.
4. ClinicalTrials.gov. Aldesleukin (interleukin-2) study listings and trial statuses. U.S. National Library of Medicine.
5. ESMO. Metastatic melanoma and renal cell carcinoma clinical practice guideline updates (historical IL-2 positioning). European Society for Medical Oncology.